Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination

Jeantin, Lina; Hesters, Adèle; Fournier, Dorine; Lebrun‐Vignes, Bénédicte; Méneret, Aurélie; Papeix, Caroline; Maillart, Élisabeth

doi:10.1007/s00415-022-11130-x

Cited by 8 publications

(2 citation statements)

References 13 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, several cases of CNS demyelination after vaccination against SARS-CoV-2 have been published. 18 However, the number of corresponding NMOSD 17 , 18 , 37 - 39 and MOGAD 19 , 40 cases is very small, especially compared with more than 12 billion administered SARS-CoV-2 vaccination doses worldwide so far. 41 This study underlines that in the case of clinical signs compatible with NMOSD or MOGAD in temporal association with a vaccination against SARS-CoV-2, an appropriate diagnostic workup should be performed to establish a therapy as soon as possible to avoid long-term sequelae.…”

Section: Discussionmentioning

confidence: 99%

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Hümmert

Bütow²,

Tkachenko³

et al. 2023

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

Background and ObjectivesTo evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated diseases (MOGAD).MethodsThis multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire. Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database.ResultsOne hundred eighty-seven patients (75% women; median age 47 [range 21–86] years; median disease duration 5.5 [range 0–67] years; median Expanded Disability Status Scale 2.0 [range 0–8.0]; 51% aquaporin-4 immunoglobulin G (AQP4-IgG)-positive, 36% myelin oligodendrocyte glycoprotein (MOG)-IgG-positive 13% double-seronegative) were analyzed. Most patients maintained excellent access to healthcare services throughout the pandemic. Immunotherapy was not changed in 88% of patients. Ninety-one percent of all patients were satisfied with medical care during the pandemic. Nearly two-thirds (64%) of patients rated their risk of infection with SARS-CoV-2 as low or moderate. Among this study sample, 23 patients (12%) knowingly acquired an infection with SARS-CoV-2 and predominantly had a nonsevere course of illness (n = 22/23, 96%). The SARS-CoV-2 vaccination rate was 89%, with 4 cases of confirmed attack or first manifestation of NMOSD/MOGAD occurring in temporal association with the vaccination (range 2–9 days). The reported HRQoL did not decline compared with a prepandemic assessment (mean EQ-5D-5L index value 0.76, 95% bootstrap confidence interval [CI] 0.72–0.80; mean EQ-VAS 66.5, 95% bootstrap CI 63.5–69.3).DiscussionThis study demonstrates that, overall, patients with NMOSD/MOGAD affiliated with specialized centers received ongoing medical care during the pandemic. Patients' satisfaction with medical care and HRQoL did not decrease.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Hümmert

Bütow²,

Tkachenko³

et al. 2023

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

show abstract

“…We included case reports and systematic reviews that specifically focused on the new onset of MOGAD after COVID-19 vaccination, while excluding other articles. In a total of 17 case reports and 1 systematic review, 53 cases were documented in patients who developed symptoms within 1-42 days of vaccination (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29). The ages of the patients ranged from 15 to 68 years old, with no sexual predilection.…”

Section: Discussionmentioning

confidence: 99%

Association of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease with Coronavirus Disease 2019 Vaccination and Infection: A Case Report of Cortical Encephalitis and Transverse Myelitis Relapse

Himeno,

Tateishi,

Irie

et al. 2023

Intern. Med.

View full text Add to dashboard Cite

We herein report a case of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) that occurred following coronavirus disease 2019 (COVID-19) vaccination and its subsequent relapse after COVID-19 infection. A 34-year-old woman developed cortical encephalitis in the right temporoparietal lobe one week after receiving the mRNA-1273 vaccine. The cerebrospinal fluid was positive for anti-MOG antibody. Her symptoms gradually improved after three courses of intravenous methylprednisolone therapy. Six months later, she experienced a relapse of transverse myelitis following COVID-19 infection. Despite treatment with plasma exchange, the patient remained paralyzed in both lower limbs. We herein review the relationship between MOGAD and COVID-19 vaccination/infection.

show abstract

Acetazolamide/azd-1222

2022

Reactions Weekly

View full text Add to dashboard Cite

Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination

Cited by 8 publications

References 13 publications

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Association of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease with Coronavirus Disease 2019 Vaccination and Infection: A Case Report of Cortical Encephalitis and Transverse Myelitis Relapse

Acetazolamide/azd-1222

Contact Info

Product

Resources

About